Gilead’s Kite taps Eisai cancer vet Amoroso to lead the charge for CAR-T sales

Just one month after naming a new head of corporate development, Gilead is beefing up its top management team again—this time plucking an oncology vet to head up its entrance into the burgeoning market for CAR-T cancer treatments.